Abstract Number: 1986 • ACR Convergence 2022
Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, autoimmune disease, which normally is characterized by inflammation and thickening of the synovial membrane leading to swollen and…Abstract Number: 2003 • ACR Convergence 2022
Anti-rheumatic Treatment Modulates Expression of the Glycolytic Enzyme PFKFB3 in CD14+ Monocytes of Patients with Rheumatoid Arthritis, Which Contributes to Dissimilarities of the IFN Signature
Background/Purpose: Combination of IFN-stimulated genes known as IFN signature, helps to predict disease activity and treatment response in several autoimmune diseases, including rheumatoid arthritis (RA).…Abstract Number: 2180 • ACR Convergence 2022
Transfer of Monoclonal ACPAs Induces Pain, Bone Loss and Tenosynovitis in Mice in a Peptidyl Arginine Deiminase-4 Dependent Manner
Background/Purpose: The appearance of anti-citrullinated protein antibodies (ACPAs) in the circulation represents a major risk factor for developing rheumatoid arthritis (RA). Here we studied whether…Abstract Number: 2248 • ACR Convergence 2022
Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort
Background/Purpose: Subpleural interstitial lung abnormalities (ILA) may be a form of subclinical or preclinical interstitial lung disease (ILD) and have been reported in up to…Abstract Number: 0055 • ACR Convergence 2022
Protective Role for Mast Cells in TNF-induced Inflammatory-Erosive Arthritis and Its Associated Lymphatic Dysfunction in Mice
Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1). Mast cells (MCs) regulate lymphatic vessels by releasing inflammatory and vasoactive mediators (e.g. histamine) (2). Previous…Abstract Number: 0113 • ACR Convergence 2022
Escalation to Biologics After Methotrexate Among US Veterans with Rheumatoid Arthritis Living in Rural versus Urban Areas
Background/Purpose: Timely diagnosis and initiation of appropriate treatments are imperative to improve outcomes for patients with rheumatoid arthritis (RA). Racial and ethnic disparities in RA…Abstract Number: 0231 • ACR Convergence 2022
Primary Care Physician’s Perspective and Needs on Early Rheumatoid Arthritis Diagnosis: REUCARE Program for Early Referral
Background/Purpose: Primary care physicians (PCPs) play a crucial role in early recognition and rapid referral of patients with inflammatory arthritis to improve early management and…Abstract Number: 0256 • ACR Convergence 2022
Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Different Circulating Auto-antibody Repertoires
Background/Purpose: RA is commonly diagnosed through a serological test for the presence of ACPA, and RA patients who test positive are collectively known as 'ACPA-positive…Abstract Number: 0272 • ACR Convergence 2022
Long-Term Efficacy of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Bdmards: Results from RA-BEYOND up to 6.9-Years of Treatment
Background/Purpose: Baricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, is approved for treatment of adults with moderately-to-severely active rheumatoid arthritis (RA). BARI demonstrated efficacy…Abstract Number: 0290 • ACR Convergence 2022
Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)
Background/Purpose: The "ORAL Surveillance" study1 suggests an increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to TNF-inhibitors (TNFi). Currently, there…Abstract Number: 0307 • ACR Convergence 2022
Reduction in Structural Damage Progression and Improvement in Clinical Response with Abatacept Treatment in Patients with ACPA+, Early RA: Results from a Post Hoc Analysis of the AVERT-2 Study by Baseline Erosion Scores
Background/Purpose: Presence of structural damage is an important risk factor for further damage progression over time in RA. Inhibition of damage progression is a key…Abstract Number: 0530 • ACR Convergence 2022
Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)
Background/Purpose: Development of the clinical phase of rheumatoid arthritis (RA) is preceded by an autoimmune phase, characterized by the presence of anti-citrullinated protein antibodies (ACPA),…Abstract Number: 0585 • ACR Convergence 2022
Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Baricitinib is a selective small molecule inhibitor of JAK 1…Abstract Number: 0604 • ACR Convergence 2022
Altered Metabolic State in Myeloid Precursors and Mature Cells Within Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterised by synovial inflammation and joint destruction. Prior research has revealed perturbation in the myeloid compartment of…Abstract Number: 0622 • ACR Convergence 2022
Commensal Reactive T-cells Display Diverse Phenotype in Rheumatoid Arthritis Patients
Background/Purpose: Past studies have shown a critical link between alteration in human commensal microbiota and development of Rheumatoid Arthritis (RA), however how CD4+ T-cell responses…
- « Previous Page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- …
- 188
- Next Page »